Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma

INTRODUCTION: Diagnosis of Alzheimer's disease (AD) based on amyloid beta (A), pathologic tau (T), and neurodegeneration (N) biomarkers in peripheral fluids promises to accelerate clinical trials and intercept disease earlier. METHODS: Qualification of a Simoa plasma p217+tau assay was performe...

Descripción completa

Detalles Bibliográficos
Autores principales: Triana‐Baltzer, Gallen, Moughadam, Setareh, Slemmon, Randy, Van Kolen, Kristof, Theunis, Clara, Mercken, Marc, Kolb, Hartmuth C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Blood‐based Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158165/
https://www.ncbi.nlm.nih.gov/pubmed/34095436
http://dx.doi.org/10.1002/dad2.12204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158165/
https://www.ncbi.nlm.nih.gov/pubmed/34095436
http://dx.doi.org/10.1002/dad2.12204

Ejemplares similares